accacc2022acc2023acc2024acuteaddressingadjuvantadvancedahaanalysisartarterialasco2021ashash2021ash2023ash2024asthmaatrialbasedbccbenefitsbetabetterbloodbreakingbreastcancercarcinomacardiovascularcarecellcervicalchallengeschemotherapychest2024choicecholesterolchronicclinicalcllcombinationcontrolcopdcoronarycovidcurrentdatadiabetesdiagnosisdiseasediseasesdosedrugsearlyeaseasd2022effectefficacyehaeha2025ehra2022ersers2024escesc2021esc2022esc2023esc2024eshesh2022esh2023esh2024esh2025esmoesmo2021esmo2023esmo2024eular2024eventsevidencefailurefibrillationfirstfocusfocusedfreefuturegallenglpguidelineguidelineshealthhearther2hfpefhighhighlightshrhypertensionimmuneimmunotherapyimportanceimproveimprovesinfluenzainhibitorinhibitorsinsightsinterviewisth2022iwlhjointkeynotekidneylandscapelargelateldlleukemialifelipidlongloweringlunglymphocyticlymphomamanagementmelanomametastaticmultiplemyeloidmyelomanavigatingnovelnoveltiesobesityoptimaloptionsoutcomesoverallpacingpatientpatientspembrolizumabpeoplephaseplacebopluspositivepostpracticepressurepreventionprimaryprogressionprostatepulmonaryrandomizedrealreceptorrefractoryrenalrespiratoryresponseresultsriskrolesabcs2024screeningsemaglutideseveresglt2showssitcstagestandardstatestudysurvivalsymposiumsyndromestargetedtermtherapeutictherapiestherapytreattreatmenttrialtrialstripleupdateupdatesvaccinationvaccineversuswcclworldwvcdc